Abiopharma

🔍 Shapiro Benjamin (Director)

Company: ORAMED PHARMACEUTICALS INC. (ORMP)

Report Date: 2025-12-31

Detailed Transactions and Holdings:

• Acquired 30,000 shares of Common Stock (Direct)
  Date: 2025-12-31 | Code: A | equity_swap_involved: 0 | shares_owned_after: 119,720.00 | transaction_form_type: 4 | Footnotes: F1, F1
• Acquired 3,500 shares of Common Stock (Direct)
  Date: 2025-12-31 | Code: A | equity_swap_involved: 0 | shares_owned_after: 123,220.00 | transaction_form_type: 4 | Footnotes: F2, F2
• Holds 0 shares of Common Stock (Direct)
  Date: 2025-12-31 | Code: H | nature_of_ownership: By trust | shares_owned_after: 1,900,000.00 | Footnotes: F3

Footnotes:

• F1: Represents Restricted Stock Units ("RSUs"). The RSUs will vest ratably in three annual tranches beginning January 1, 2027. Each RSU represents the right to receive one share of common stock, par value $0.012 per share ("Common Stock"), of the Issuer.
• F2: Represents RSUs. The RSUs will vest in quarterly installments over a one-year period starting April 1, 2026. Each RSU represents the right to receive one share of Common Stock of the Issuer.
• F3: These shares of Common Stock are held by a trust of which the reporting person is a trustee and beneficiary.